94 related articles for article (PubMed ID: 12208412)
1. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication.
Rajagopalan S; Trachtenberg J; Mohler E; Olin J; McBride S; Pak R; Rasmussen H; Crystal R
Am J Cardiol; 2002 Sep; 90(5):512-6. PubMed ID: 12208412
[TBL] [Abstract][Full Text] [Related]
2. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial.
Mohler ER; Rajagopalan S; Olin JW; Trachtenberg JD; Rasmussen H; Pak R; Crystal RG
Vasc Med; 2003; 8(1):9-13. PubMed ID: 12866606
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.
Rajagopalan S; Shah M; Luciano A; Crystal R; Nabel EG
Circulation; 2001 Aug; 104(7):753-5. PubMed ID: 11502697
[TBL] [Abstract][Full Text] [Related]
5. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
Rajagopalan S; Mohler E; Lederman RJ; Saucedo J; Mendelsohn FO; Olin J; Blebea J; Goldman C; Trachtenberg JD; Pressler M; Rasmussen H; Annex BH; Hirsch AT;
Am Heart J; 2003 Jun; 145(6):1114-8. PubMed ID: 12796772
[TBL] [Abstract][Full Text] [Related]
6. Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle.
Poliakova L; Kovesdi I; Wang X; Capogrossi MC; Talan M
J Thorac Cardiovasc Surg; 1999 Aug; 118(2):339-47. PubMed ID: 10425008
[TBL] [Abstract][Full Text] [Related]
7. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor.
Magovern CJ; Mack CA; Zhang J; Rosengart TK; Isom OW; Crystal RG
Hum Gene Ther; 1997 Jan; 8(2):215-27. PubMed ID: 9017425
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication.
Lee TM; Su SF; Tsai CH; Lee YT; Wang SS
Clin Sci (Lond); 2001 Sep; 101(3):305-11. PubMed ID: 11524048
[TBL] [Abstract][Full Text] [Related]
9. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Rosengart TK; Lee LY; Patel SR; Kligfield PD; Okin PM; Hackett NR; Isom OW; Crystal RG
Ann Surg; 1999 Oct; 230(4):466-70; discussion 470-2. PubMed ID: 10522716
[TBL] [Abstract][Full Text] [Related]
10. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Hedman M; Hartikainen J; Syvänne M; Stjernvall J; Hedman A; Kivelä A; Vanninen E; Mussalo H; Kauppila E; Simula S; Närvänen O; Rantala A; Peuhkurinen K; Nieminen MS; Laakso M; Ylä-Herttuala S
Circulation; 2003 Jun; 107(21):2677-83. PubMed ID: 12742981
[TBL] [Abstract][Full Text] [Related]
11. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia.
Shyu KG; Chang H; Wang BW; Kuan P
Am J Med; 2003 Feb; 114(2):85-92. PubMed ID: 12586226
[TBL] [Abstract][Full Text] [Related]
12. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121.
Patel SR; Lee LY; Mack CA; Polce DR; El-Sawy T; Hackett NR; Ilercil A; Jones EC; Hahn RT; Isom OW; Rosengart TK; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1331-48. PubMed ID: 10365664
[TBL] [Abstract][Full Text] [Related]
13. Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
Rajagopalan S; Olin JW; Young S; Erikson M; Grossman PM; Mendelsohn FO; Regensteiner JG; Hiatt WR; Annex BH
Hum Gene Ther; 2004 Jun; 15(6):619-24. PubMed ID: 15212720
[TBL] [Abstract][Full Text] [Related]
14. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
Creager MA; Olin JW; Belch JJ; Moneta GL; Henry TD; Rajagopalan S; Annex BH; Hiatt WR
Circulation; 2011 Oct; 124(16):1765-73. PubMed ID: 21947297
[TBL] [Abstract][Full Text] [Related]
15. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Harvey BG; Maroni J; O'Donoghue KA; Chu KW; Muscat JC; Pippo AL; Wright CE; Hollmann C; Wisnivesky JP; Kessler PD; Rasmussen HS; Rosengart TK; Crystal RG
Hum Gene Ther; 2002 Jan; 13(1):15-63. PubMed ID: 11779412
[TBL] [Abstract][Full Text] [Related]
16. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.
Henry TD; Annex BH; McKendall GR; Azrin MA; Lopez JJ; Giordano FJ; Shah PK; Willerson JT; Benza RL; Berman DS; Gibson CM; Bajamonde A; Rundle AC; Fine J; McCluskey ER;
Circulation; 2003 Mar; 107(10):1359-65. PubMed ID: 12642354
[TBL] [Abstract][Full Text] [Related]
17. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector.
Magovern CJ; Mack CA; Zhang J; Hahn RT; Ko W; Isom OW; Crystal RG; Rosengart TK
Ann Thorac Surg; 1996 Aug; 62(2):425-33; discussion 433-4. PubMed ID: 8694601
[TBL] [Abstract][Full Text] [Related]
18. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Delis KT; Nicolaides AN; Wolfe JH; Stansby G
J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
[TBL] [Abstract][Full Text] [Related]
19. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
[TBL] [Abstract][Full Text] [Related]
20. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
Crystal RG; Harvey BG; Wisnivesky JP; O'Donoghue KA; Chu KW; Maroni J; Muscat JC; Pippo AL; Wright CE; Kaner RJ; Leopold PL; Kessler PD; Rasmussen HS; Rosengart TK; Hollmann C
Hum Gene Ther; 2002 Jan; 13(1):65-100. PubMed ID: 11779413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
